



## Clinical review of total parenteral nutrition use among pediatric: Critics and outcomes

Yelly Oktavia Sari<sup>1,2\*</sup>, Mohd Baidi Bahari<sup>3</sup> and Baharudin Ibrahim<sup>2</sup>

1, Faculty of Pharmacy, Andalas University, Padang 25163, Indonesia

2, Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM)

3, Faculty of Pharmacy, Aimst University Kedah

### Abstract

The introduction of total parenteral nutrition (TPN) as an alternative nutrition provided a life saving solution to children with chronic bowel obstructions, fistulas, loss of mucosal body surfaces, short bowel syndrome, and other clinical problems that precluded enteral diet by mouth or tube feeding for long periods of time. Intravenous administration of TPN became an essential fluid to meet nutritional needs and to avoid progressive starvation-induced malnutrition, which changed the outcome of patients from dying. As a result, the prognosis for patients with SBS has changed dramatically and the management with the expected survival for infants with congenital gastrointestinal anomalies and gut failure has improved significantly. However, its use has been shown to associate with an increased incidence of infection. Routine laboratory monitoring may include serum electrolytes, glucose, blood urea nitrogen (BUN), creatinine, calcium, phosphorus, magnesium, albumin, pre-albumin, complete blood count with differential, and iron indices as well as assessment of acid-base status. Routine monitoring of laboratory values is not indicated for medically stable pediatric patients receiving EN at advised levels and achieving adequate growth. There are 2 fatty acids in humans that must be supplied via the diet primarily from plants. They are linoleic and  $\alpha$ -linolenic acid and are known as essential fatty acids (EFAs). Patients receiving EN and PN must be adequately supplemented with both EFAs because their oral intake may be minimal. If inadequate amounts are provided, an essential fatty acid deficiency (EFAD) may eventually occur.

Key-Words: TPN, Pediatrics, Clinical care, Parenteral nutritions

### Introduction

In the late 1960's, the introduction of total parenteral nutrition (TPN) as an alternative nutrition provided a life saving solution to children with chronic bowel obstructions, fistulas, loss of mucosal body surfaces, short bowel syndrome, and other clinical problems that precluded enteral diet by mouth or tube feeding for long periods of time. Intravenous administration of TPN became an essential fluid to meet nutritional needs and to avoid progressive starvation-induced malnutrition, which changed the outcome of patients from dying<sup>1</sup>. Since then, TPN has been a gold standard practice in treatment and a panacea for infants and children who are unable to eat or to absorb enterally provided nutrients<sup>1-4</sup>. As a result, the prognosis for patients with SBS has changed dramatically and the management with the expected survival for infants with congenital gastrointestinal anomalies and gut failure have improved significantly<sup>5-6</sup>.

However, its use has been shown to associate with an increased incidence of infection<sup>7</sup>. A number of independent experimental studies have been carried out shown that intravenous TPN negatively influences gut barrier functions and mucosal immunity while withholding nutrients by mouth or enteral tube feeding, after the resection of small intestine. These studies demonstrated

that TPN is associated with: 1) increases in intestinal permeability, bacterial overgrowth, and bacterial translocation, 2) rapid changes in gut-associated lymphoid tissue (GALT) T cells, B cell, and secretory immunoglobulin A (S-IgA) levels, 3) impairment in IgA-mediated mucosal immunity defenses in the respiratory tract, 4) impairment in neutrophil function, 5) alteration in gastrointestinal (GI) architecture or mucosal atrophy<sup>8-14</sup>. This paper presents a descriptive systematic review of published research articles on the effects of the long-term TPN on gut mucosal immunity in children with SBS; specifically, it addresses whether TPN: 1)

\* Corresponding Author

Email: yelly.sari@gmail.com

promotes bacterial translocation, 2) impairs intestinal mucosal immunity by decreasing S-IgA levels, 3) inhibits neutrophil and cytokine functions in blood, 4) promotes atrophy of the mucosal villi, 5) hyperglycemia, and 6) causes death. It is hoped that these findings will expand the knowledge of

pediatric nurses, and have an impact on clinical practice by being included in the pediatric parenteral nutritional guidelines. Since the review of literature did not reveal any systematic reviews of TPN and mucosal immunity on children with SBS, the aim of this descriptive systematic review of individually published scientific studies is to impart a better understanding of the effects of TPN on gut mucosal defense and barrier function. Short bowel syndrome, one of the major indications for diagnostic categories using long-term TPN<sup>15</sup>, is a clinically complex disorder resulting from multiple alterations of normal intestinal anatomy and physiology and producing a variety of nutritional, infectious, and metabolic complications because of impairment caused by vascular disease, intestinal volvulus, ischemic bowel, inflammatory bowel, and necrotizing enterocolitis (NEC)<sup>16-17</sup>. SBS is also described as, "the malabsorptive state" that mostly follows massive resection of the small intestine<sup>18-19</sup>.

After resection, the residual or remaining small bowel undergoes intestinal adaptation, a process characterized by mucosal hyperplasia, villus lengthening, increased crypt depth (intestinal gland), and bowel dilation. The process of adaptation is complex and includes both structural and functional changes. The earliest sign can be detected within 24-48 hours, and process may continue for months, possibly years. In the early phase, mucosal hyperplasia and villus hypertrophy occur. Oral nutrients and hormones stimulate this intestinal adaptation. The main clinical challenge in SBS lies in managing the many nutritional problems that occur as a result of malabsorption secondary to the reduced absorptive surface area<sup>20-21</sup>.

#### a. Short Gut Syndrome

Short bowel syndrome (SBS) is defined as the malabsorptive state that often follows massive resection of the small intestine. Most cases originate in the newborn period and result from congenital anomalies. It is associated with a high morbidity, is potentially lethal and often requires months, sometimes years, in the hospital and home on total parenteral nutrition (TPN). Long-term survival without parenteral nutrition depends upon establishing enteral nutrition and the process of intestinal adaptation through which the remaining small bowel gradually increases its absorptive capacity. The purpose of this article is to perform a descriptive systematic review of the

published articles on the effects of TPN on the intestinal immune system investigating whether long-term TPN induces bacterial translocation, decreases secretory immunoglobulin A (S-IgA), impairs intestinal immunity, and changes mucosal architecture in children with SBS<sup>22</sup>.

#### b. Microvillus Inclusion Disease (MVID)

##### *Clinical presentation*

Pregnancy and delivery are uneventful; in general, there is no notion of polyhydramnios except in rare isolated cases. Severe watery diarrhea starts within the first days of life<sup>23-28</sup>. This diarrhea becomes so abundant, that within 24h the children can lose up to 30% of their body weight, resulting in profound metabolic acidosis and severe dehydration. MVID is most often severe and life-threatening. Accurate quantification of the stool volumes reveals 150 to over 300 ml/kg/d, with a high sodium content (approximately 100 mmol/L). Complete and prolonged bowel rest allows to reduce stool volume moderately, but volumes nearly always remain above 150 ml/kg/day<sup>26</sup>. Inappropriate parenteral nutrition with steadily increasing intravenous fluids may significantly aggravate stool output. No additional clinical signs are associated with MVID; in particular, there are no malformations or involvement of other organs such as liver, kidney etc. However, a small number of children have a massive pruritus secondary to marked elevations in the concentrations of biliary acids in the blood. Initially, no intestinal and colonic loops. All children with congenital MVID urgently require total parenteral nutrition (TPN), which often causes rapidly evolving cholestasis and liver disease. A detailed multicenter analysis of 23 patients with MVID<sup>26</sup> allowed two different forms and presentation of MVID to be distinguished on a clinical and morphological basis: congenital early-onset MVID (starting within the first days of life), and late-onset MVID (with first symptoms appearing after two or three months of life).

##### *Outcome*

MVID is a constitutive intestinal epithelial cell disease that causes an irreversible diarrheal disorder leading to permanent and definitive intestinal failure<sup>26,28-29</sup>. Children with MVID are dependent on exclusive parenteral nutrition throughout their lives. Oral alimentation and appropriate oral caloric intake are impossible. There is no hope for improvement with age. A large number of patients do not survive the first three years of life as a result of infectious complications or rapid evolution, and renal complication. In contrast to children with early-onset MVID, the diarrhea is often less severe in children with the late-onset form of the disease. With age, children

with late-onset MVID can acquire partial intestinal autonomy, resulting in a reduction of the number of perfusions of parenteral nutrition to one or two a week. Beyhan Duran *et al*) identified five themes: 1) sepsis, 2) impaired immune functions: *In vitro* studies, 3) mortality, 4) villous atrophy, 5) duration of dependency on TPN after bowel resection.

### 1. Sepsis

Six of the 13 trials reported bacterial overgrowth, sepsis, or septicemia<sup>30-36</sup>. In the first study,<sup>180</sup> investigators reported that two children died from gram-positive central venous catheter infections. In the second study<sup>35</sup>, researchers compared a total of 49 neonates with 7 SBS who were on TPN and 42 weaned children. It was ascertained that the occurrence of bacterial overgrowth was related to small bowel length. Eleven TPN weaned subjects who had bacterial overgrowth had a mean bowel length of 54 cm as compared to 105 cm in those without bacterial growth. In Pierro and colleagues' study<sup>36</sup>, 41 children whose surveillance cultures developed abnormal carriage. These investigators stated that infants receiving TPN are at a very low risk of developing sepsis and septicemia as long as their surveillance cultures reveal normal flora only. Conversely, the presence of abnormal PPM in the throat and/or the gut increases the risk of sepsis and septicemia to about 25% of the population at risk. They have also stated that the sicker and more physiologically stressed infants would not regain normal gut function as fast as neonates who were doing clinically better. In the third study<sup>31</sup>, the purpose of the investigation was to demonstrate an association between microorganisms that were carried in the digestive tract and present in the blood of infants with sepsis who were receiving TPN. Sepsis occurred in 15 patients (43 episodes) and 10 patients experienced septicemia (24 episodes). Six infants had 15 episodes of bacterial translocation due to *E. coli*, *Klebsiella*, *Candida* species and enterococci. Eight patients had nine episodes of septicemia caused by coagulase-negative staphylococci. The researchers concluded that there was an association between septicemia and elevated serum bilirubin level, indicating TPN related cholestasis. Dahlstrom<sup>32</sup> investigated a total of 29 children, most of whom had SBS and had been on TPN for 2 years. Children receiving TPN for an average of 2 years developed low biochemistry levels. The children were divided into two groups. The children in group I were estimated to have absorbed less than 5% of their daily caloric intake from the intestinal tract, while intake in the children in group II was 30-70%. Based on previous animal studies, the investigator predicted that the low

lymphocyte count was related to extensive bowel resection, (the average bowel length of group I was <25 cm). Eleven of these children eventually died from TPN related sepsis, septicemia, central line infections, or cholestatic liver diseases.

### 2. Impaired immune functions: in vitro studies

In three *in-vitro* control studies, investigators elucidated that long-term TPN in infants suppresses specific mechanisms of immune functions<sup>37-39</sup>. In the first study, Okada and colleagues (1999) investigated the effects of TPN solution on neutrophil phagocytosis and whole blood cytokine production in response to coagulase-negative staphylococci in an *in vitro* challenge in five enterally fed infants (age <6 months) and 6 healthy adults. They found that in infants, after 2 hours of incubation with a physiological dose of TPN (1  $\mu$  of TPN in 1 ml of blood) there was a significant decrease ( $P < 0.05$ ) in tumor necrosis factor alpha (TNF- $\alpha$ ) production. The other two *in vitro* controlled-clinical trials focused on the cellular mechanism of neutrophil dysfunction, and the whole blood bactericidal activity against coagulase negative staphylococci in the infants receiving TPN<sup>37-39</sup>. These investigators used an *in vitro*-controlled whole blood model to measure the host bactericidal activity against coagulase-negative staphylococci. When researchers added coagulase-negative staphylococci to whole blood drawn from control patients receiving enteral feeding, the median killing of coagulase-negative staphylococci was 65%. In contrast, blood from infants receiving long-term TPN failed to kill this organism as effectively. Infants on long-term TPN had the lowest levels of both whole blood and intracellular killing of coagulase-negative staphylococci due to a defect in neutrophil function. These investigators reported that there was a negative linear correlation between the duration of TPN in days and killing of coagulase-negative staphylococci ( $P = 0.002$ ). For every additional week of TPN, there was a 7% reduction in killing of coagulase-negative staphylococci. These investigators also noted that there was a significant positive correlation between neutrophil count and killing of coagulase-negative staphylococci ( $r = 0.80$ ,  $P = 0.001$ ).

### 3. Mortality

A total of 34 TPN complicated deaths were reported in five of the 13 clinical trials. Of these 34 deaths, 7 children died from SBS, 12 from sepsis, respiratory infections, and low immune deficiency, and other 15 from liver failure<sup>32,34-35,40</sup>.

#### 4. Duration of dependency on TPN after bowel resection

There were only three studies, retrospective and case study that showed the dependency on TPN in infants who had undergone resection of the small intestine<sup>34,41-42</sup>. As reported in these studies, there were only 17 children who were totally dependent on TPN, and nine of them died while on TPN. In one of these studies, investigators also noticed that no child successfully discontinued TPN after 36 months of age<sup>42</sup>. They concluded that children dependent on TPN at or more than 36 months of age are permanently dependent on TPN. Andorsky and his coworkers<sup>34</sup> also emphasized that residual bowel length was highly correlated with duration of TPN. Their conclusion was that remaining functional small bowel length was an independent predictor of successful weaning. Although most children had difficulty being weaned from TPN in other studies, Bines and her co-workers<sup>41</sup> were able to wean all four children from TPN within 15 months of initiation of a study formula. They used an amino acidbased complete infant formula (Neocate, SHS Inc, Rockville, MD, USA) as enteral feeding. Small bowel length of these children was documented between 40 cm to 80 cm with no ileocecal, and in only one child had 13 cm with ileocecal present. All patients had repeated esophagogastroduodenoscopy and colonoscopy or jejunoscopy with findings of mild, nonspecific neutrophilic inflammation involving areas from biopsy specimens from upper and lower intestinal tract. In addition, two other studies used enteral formulas while children were on TPN. Andorsky and colleagues<sup>34</sup> fed the patients with continuous breast milk or protein hydrolysate formula. Of the 30 patients in the study, 20 were weaned from TPN. Based on their report, median residual bowel length was 61 cm, and ileocecal valve was preserved in 57% of the patients. There was a significant high correlation between use of breast milk and shorter the duration of TPN. Infants who received breast milk were weaned from TPN in 290 days versus 720 days in non-breast-fed infants<sup>44-48</sup>.

#### 5. Villous atrophy

In two separate clinical trials, researchers<sup>41,43</sup> examined whether the effects of TPN on the intestines of children are similar to those reported in animals. In the Rosi and colleagues' study, a total of 32 children (ages 9 months to 19 years) were involved. Based on the biopsy results, the investigators reported that 3 of the 4 patients receiving long-term parenteral nutrition for short-bowel syndrome (TPN >7 months) had mild villous atrophy. Biopsies from 3 patients in the inflammatory bowel disease (IBD) group (TPN = 1 month) did not exhibit atrophy. Bines and colleagues<sup>49</sup>

also reported similar results; in their study only one of four children (bowel length, 40 cm) had partial villous atrophy of the small intestinal mucosa.

#### Monitoring Laboratory Values in Pediatrics TPN

Routine laboratory monitoring may include serum electrolytes, glucose, blood urea nitrogen (BUN), creatinine, calcium, phosphorus, magnesium, albumin, pre-albumin, complete blood count with differential, and iron indices as well as assessment of acid-base status<sup>50-51</sup>. Routine monitoring of laboratory values is not indicated for medically stable pediatric patients receiving EN at advised levels and achieving adequate growth<sup>52</sup>. Serum zinc may need to be monitored when fat malabsorption is present. Physical assessment including clinical signs of nutrient excess.

Prealbumin is commonly used to monitor protein status due to its shorter half-life of 2 to 3 days in comparison to albumin<sup>53</sup>. However; there are other factors that can influence prealbumin levels such as inflammatory states, end-stage liver disease, untreated thyroid disease, renal disease, and zinc deficiency. These limitations should be considered when interpreting a patient's prealbumin level<sup>54-56</sup>. Monitoring of prealbumin levels can be helpful especially for long-term stable patients. Prealbumin can be monitored on a weekly basis initially and then monthly in stable patients. Changes in triglyceride levels can be influenced by a variety of factors including disease state, organ function, medications, nutrition status, and current nutrient intake. They should be monitored daily when SNS is initially started, followed by a weekly level, and then increased to monthly<sup>57-60</sup>. Carnitine is often supplemented in the formula of PN patients, particularly neonates and infants due to their inability to synthesize an adequate amount. In addition, premature neonates will also have limited carnitine stores that are needed for long-chain fatty acid transport<sup>61</sup>. A deficient patient may present with increased triglyceride levels, hyperbilirubinemia, or decreased weight gain along with a multitude of other clinical symptoms<sup>62-64</sup>. Currently a carnitine dose of 10 to 20 mg/kg/d is recommended for IV or oral supplementation and should be initiated in any patient receiving PN for > 7 days<sup>61</sup>. Although most EN formulas contain adequate dietary carnitine, supplementation can be considered in EN patients with malabsorption or bowel resection if deficiency is suspected or confirmed by laboratory testing<sup>65</sup>. A carnitine profile, including ester/free ratio, should be monitored every 3 to 6 months if the patient is being supplemented. A yearly carnitine profile is sufficient for patients not receiving supplementation<sup>66</sup>.

There are 2 fatty acids in humans that must be supplied via the diet primarily from plants. They are linoleic and  $\alpha$ -linolenic acid and are known as essential fatty acids (EFAs)<sup>67</sup>. Patients receiving EN and PN must be adequately supplemented with both EFAs because their oral intake may be minimal. If inadequate amounts are provided, an essential fatty acid deficiency (EFAD) may eventually occur. If lipid-free PN is provided for a significant amount of time or there is clinical manifestation of an EFAD, it is possible to order an EFA profile. The resulting triene:tetraene ratio can determine if an EFAD exists<sup>58,65-67</sup>.

**Table 1: Contents of TPN and monitoring plans**

PARAMETER	INITIAL	FOLLOW-UP
BMP	Daily	Included in
CMP	Weekly	CMP
Magnesium	Daily to	Every 1 to 4
Phosphorous	Weekly	weeks
Prealbumin	Daily to	Every 1 to 4
Triglycerides	Weekly	weeks
PT/INR	Weekly	Every 1 to 4
CBC differential/ platelets	Daily to	weeks
GGT	Weekly	Monthly
	Weekly	Monthly
	Weekly	Monthly
	Baseline if indicated	Every 1 to 4 weeks
		Monthly

**Table 2: Nutritional contents and monitoring issues**

PARAMETER	INITIAL	FOLLOW-UP
Iron Studies	3 mo	Every 3-6 mo
Zinc	3 mo	Every 3-6 mo
Selenium	3 mo	Every 3-6 mo
Manganese	3 mo	Every 3-6 mo
Copper	3 mo	Every 3-6 mo
Chromium	3 mo	Every 3-6 mo
Vitamins A, D, and E	6 mo	Every 12 mo
Vitamin B12 and Folate	3 mo	Every 3-12 mo
Carnitine	Baseline if indicated	Every 12 mo
TSH		

**Drug Compatibilities in Pediatrics TPN**

Drugs Compatible with Parenteral Nutrition\*

The tables below list the drugs that are compatible with parenteral nutrition and those that are not. For the most recent information, see the current SickKids Formulary of Drugs<sup>68</sup>.

**Table 3: List of drugs compatible with Parenteral Nutritions**

Ampicillin	Fluconazole	Metoclopramide
Cefazolin	Furosemide	Morphine
Cefotaxime	Gentamicin	Norepinephrine
Ceftazidime	Heparin	Penicillin G
Cefuroxime	Insulin	Piperacillin
Clindamycin	Iron Dextran	Ranitidine
Cloxacillin	Isoproterenol	Tazocin®
Dobutamine	Lidocaine	Tobramycin
Dopamine	Meperidine	Vancomycin
Erythromycin	Methylprednisolone	

\*For compatibility information on any drugs not listed, contact the pharmacy department.

**Drugs Incompatible with Parenteral Nutrition**

The following drugs are incompatible with PN and must not be given concurrently with a PN solution under any circumstances. These drugs may be administered through a Y-connection, provided that the PN solution is stopped and the line clamped immediately above the Y, then adequately flushed<sup>68</sup>.

**Table 4: List of drug not compatible with Parenteral Nutritions**

Acetazolamide	Cisplatin	Mannitol
Acyclovir	Cyclosporine	Metronidazole
Amphotericin	Deferoxamine	Pantoprazole
Antithymocyte (ATGAM)	Doxorubin	Phenytoin
Globulin	Etoposide	Sodium Bicarbonate
	Ganciclovir	Teniposide

- Drug compatibilities with PN solutions can never be guaranteed<sup>68</sup>.
  - If there is a separate IV site or catheter lumen available, use it for drug administration<sup>68</sup>.
  - If the PN is turned off for scheduled drug administration, cycle the total PN prescription over the number of remaining hours<sup>214</sup>.
- For drugs not listed above, the following steps are taken<sup>68</sup>

1. The pharmacist can discuss with the nurse, physician or dietitian the possibility of finding a separate IV site or turning off the PN to allow drug administration. If a patient's condition allows, new rates can be suggested that would give the required PN volume over the number of hours available.
2. If this is not possible, the pharmacist can discuss the situation with the prescribing healthcare professional. The pharmacist relays the information available on the drug and the individual patient is assessed.

3. The physician makes the decision to run (or not to run) a drug simultaneously with PN.
4. The physician documents the decision as a physician's order, e.g., Drug X may be run concurrently with PN.

In all cases where drugs are infused concurrently with PN solutions, the IV lines should be carefully monitored for signs of incompatibility.

### Discussion

Systematic reviews focus on empirical studies and seek to summarize past research by drawing overall conclusions from many separate investigations that address related or identical hypotheses<sup>44</sup>. The purpose of this descriptive systematic review was to assess the literature documenting whether TPN negatively influences gut barrier function and is associated with increases in intestinal bacterial overgrowth, bacterial translocation, increases in mucosal permeability, decreases in S-IgA levels, and changes in mucosal architecture in infants and children after small bowel resection. Thirteen clinical trials in children from 1990 to 2001 examined the effects of TPN on infection, mortality, impaired intracellular immune functions, villous atrophy, and long-term TPN dependency. These studies were conducted in four countries from various disciplines; they ranged in size from 4 to 94 children, and age from approximately 4 months to 17 years old, with the majority of children spending time in hospital. Numerous experimental studies suggest that long-term TPN has harmful effect. Evidence in experimental studies about TPN's effects on mucosal immunity and villous atrophy is very convincing<sup>45-46</sup>; however, findings in human subjects were inconsistent. Although animal models provide us wealth of evidence and continue to offer valuable information to apply to clinical conditions, Rossi and coworkers<sup>43</sup> argue that extrapolating these results to apply to the human model is inappropriate. Their study results showed that infants with SBS on TPN for more than 9 months had only minimal grade villi atrophy. They concluded that humans are more resistant to hypoplastic intestinal changes induced by TPN; and effects in humans seem to require longer periods of TPN. In adults, 203 surgical patients who had at least 10 days of preoperative TPN without enteral nutrients, no significant decrease in villous height or increase in bacterial translocation were noted compared with those on enterally fed controls<sup>47</sup>. Guedon and colleagues<sup>48</sup> performed biopsies in the duodenum of seven adults (all with inflammatory bowel disease) before TPN, after about 3 weeks of TPN, and after discontinuing TPN and restarting oral feedings. They noted no change in gross villous morphology with only

moderate decrease in microvillus height after 21 days of TPN. Buchman and colleagues<sup>49</sup>, however, found a significant decrease in villous height after 2 weeks of TPN study involving eight healthy volunteers. Although mucosal thickness decreased significantly, in contrary to animal studies, villous architecture was preserved after TPN; and five days of enteral refeeding was sufficient to reverse the intestinal morphologic changes. Pironi and colleagues<sup>50</sup> performed endoscopic biopsies in 2 adult patients who underwent long-term TPN for the treatment of a postoperative enterocutaneous fistula, and their results showed changes in villous height and crypt depth after 2 and 3 months of TPN; two months after oral refeeding, the values of morphometric parameters were significantly greater than those observed after TPN and were similar to those controls. Groos and colleagues<sup>51</sup> also conducted a study involving 20 adults to investigate whether TPN causes morphological changes in intestinal mucosa of human adults similar to those observed in animals experiments. They found jejunal mucosal atrophy, and a remodeling of luminal surface architecture with disappearance of cell shedding. (Beyhan Duran et al) Based on this exhaustive literature review, there is no direct evidence suggesting that TPN promotes bacterial overgrowth, impairs neutrophil functions, inhibits blood's bactericidal effect, causes villous atrophy, or causes to death in human model. The hypothesis relating negative effects of TPN on gut immunity remains attractive, but unproven. Enteral nutrition is cheaper, but no safer than TPN. Based on the current evidence, TPN seems to be safe and a life saving solution<sup>22</sup>.

### References

1. Kudsk KA: Current aspects of mucosal immunology and its influence by nutrition. *Am J Surg* 2002, 183:390-398.
2. Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE: Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. *Surgery* 1968, 64:134-142.
3. Buchman AL, Moukarzel AA, Bhuta S, Belle M, Ament ME, Eckhart CD, Hollander D, Gornbein J, Kopple JD, Vijayaraghavan SR: Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. *JPEN J Parenter Enteral Nutr* 1995, 19:453-460.
4. Falcone RA, Warner BW: Pediatric parenteral nutrition. In *Clinical nutrition : parenteral nutrition* 3rd edition. Edited by: Rombeau JL and Rolandelli R. Philadelphia, W.B. Saunders; 2001:476-496.

5. Chaet MS, Farrell MK, Ziegler MM, Warner BW: Intensive nutritional support and remedial surgical intervention for extreme short bowel syndrome. *J Pediatr Gastroenterol Nutr* 1994, 19:295-298.
6. Suita S, Masumoto K, Yamanouchi T, Nagano M, Nakamura M: Complications in neonates with short bowel syndrome and longterm parenteral nutrition. *JPEN J Parenter Enteral Nutr* 1999, 23:S106-9.
7. Okada Y, Klein NJ, van-Saene HK, Webb G, Holzel H, Pierro A: Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. *Ann Surg* 2000, 231:276-281.
8. Alverdy JC, Aoye E, Moss GS: Total parenteral nutrition promotes bacterial translocation from the gut. *Surgery* 1988, 104:185-190.
9. Sakamoto K, Hirose H, Onizuka A, Hayashi M, Futamura N, Kawamura Y, Ezaki T: Quantitative study of changes in intestinal morphology and mucus gel on total parenteral nutrition in rats. *J Surg Res* 2000, 94:99-106.
10. McAndrew HF, Lloyd DA, Rintala R, van-Saene HK: The effects of intravenous epidermal growth factor on bacterial translocation and central venous catheter infection in the rat total parenteral nutrition model. *Pediatr Surg Int* 2000, 16:169-173.
11. Ganessunker D, Gaskins HR, Zuckermann FA, Donovan SM: Total parenteral nutrition alters molecular and cellular indices of intestinal inflammation in neonatal piglets. *JPEN J Parenter Enteral Nutr* 1999, 23:337-344.
12. Alverdy J, Chi HS, Sheldon GF: The effect of parenteral nutrition on gastrointestinal immunity. The importance of enteral stimulation. *Ann Surg* 1985, 202:681-684.
13. King BK, Li J, Kudsk KA: A temporal study of TPN-induced changes in gut-associated lymphoid tissue and mucosal immunity. *Arch Surg* 1997, 132:1303-1309.
14. Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-Henken B: Effects of parenteral and enteral nutrition on gut-associated lymphoid tissue. *J Trauma* 1995, 39:44-51; discussion 51-2.
15. Wang HT, Sax HC: Total parenteral nutrition: effects on the small intestine. In *Clinical nutrition : parenteral nutrition* 3rd edition. Edited by: Rombeau JL and Rolandelli R. Philadelphia, W.B. Saunders; 2001:353-363.
16. Neu J, Weiss MD: Necrotizing enterocolitis: pathophysiology and prevention. *JPEN J Parenter Enteral Nutr* 1999, 23:S13-7.
17. Vanderhoof JA: Short-bowel syndrome and intestinal adaptation. In *Pediatric gastrointestinal disease : pathophysiology, diagnosis, management* 3rd edition. Edited by: Walker WA, Durie PR, Hamilton JR and Walker-Smith JA. Ontario ; New York, B.C. Decker;2000:583-602.
18. Shou J, Lappin J, Minnard EA, Daly JM: Total parenteral nutrition, bacterial translocation, and host immune function. *Am J Surg* 1994, 167:145-150.
19. Piena-Spoel M, Sharman-Koendjibiharie M, Yamanouchi T, Tibboel D: "Gut-feeling" or evidence-based approaches in the evaluation and treatment of human short-bowel syndrome. *Pediatr Surg Int* 2000, 16:155-164.
20. Serrano MS, Schmidt-Sommerfeld E: Nutrition support of infants with short bowel syndrome. *Nutrition* 2002, 18:966-970.
21. Murphy MS: The management of short bowel syndrome. *Current Paediatrics* 2001, 11:264-268.
22. Beyhan Duran, "The effects of long-term total parenteral nutrition on gut mucosal immunity in children with short bowel syndrome: a systematic review", *BMC Nursing* (2005)
23. Croft NM, Howatson AG, Ling SC, Naim L, Evans TJ, Weaver LT. Microvillous inclusion disease: an evolving condition. *J Pediatr Gastroenterol Nutr.* 2003;31:185-9.
24. Davidson GP, Cuiz E, Hamilton JR, Gall DG. Familial enteropathy: a syndrome of protracted diarrhea from birth, failure to thrive, and hypoplastic vilous atrophy. *Gastroenterology.* 1978;75:783-90.
25. Nathavitharana KA, Green NJ, Raafat F, Booth IW. Siblings with microvillous inclusion disease. *Arch Dis Child.* 1994;71:71-3.
26. Phillips AD, Schmitz J. Familial microvillous atrophy: a clinicopathological survey of 23 cases. *J Pediatr Gastroenterol Nutr.* 1992;14:380-96.
27. Schmitz J, Ginies JL, Arnaud-Battandier F, et al. Congenital microvillous atrophy, a rare cause of neonatal intractable diarrhea. *Pediatr Rs.* 1982;16:104.
28. Cutz E, Rhoads JM, Drumm B, Sherman PM, Durie PR, Forstner GG. Microvillous inclusion disease: an inherited defect of brush-border assembly and differentiation. *N Engl J Med.* 1989;320:646-51.
29. Reummele FM, Jan D, Lacaille F, Cezard JP, Canioni D, Phillips AD, Peuchmaur M, Aigrain Y, Brousse N, Schmitz J, Revillon Y, Goulet O. New perspective for children with microvillous inclusion disease: early small bowel

- transplantation. *Transplantation*. 2004 15;77:1024-8.
30. Pierro A, van-Saene HK, Jones MO, Brown D, Nunn AJ, Lloyd DA: Clinical impact of abnormal gut flora in infants receiving parenteral nutrition. *Ann Surg* 1998, 227:547-552.
  31. Pierro A, van Saene HK, Donnell SC, Hughes J, Ewan C, Nunn AJ, Lloyd DA: Microbial translocation in neonates and infants receiving long-term parenteral nutrition. *Arch Surg* 1996, 131:176-179.
  32. Dahlstrom KAB: Long Term Parenteral Nutrition in Children: A Nutritional, Metabolic and Immunological Study. Reproprint Ab, Box 21085, S-100 31 Stockholm, Sweden, Karolinska Institutet (Sweden); 1988.
  33. Weber TR: Enteral feeding increases sepsis in infants with short bowel syndrome. *J Pediatr Surg* 1995, 30:1086-8; discussion 1088-9.
  34. Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson DS, Collier SB, Lo C, Duggan C: Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. *J Pediatr* 2001, 139:27-33.
  35. Kaufman SS, Loseke CA, Lupo JV, Young RJ, Murray ND, Pinch LW, Vanderhoof JA: Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. *J Pediatr* 1997, 131:356-361.
  36. Pierro A, van. -Saene HK, Jones MO, Brown D, Nunn AJ, Lloyd DA: Clinical impact of abnormal gut flora in infants receiving parenteral nutrition. *Ann Surg* 1998, 227:547-552.
  37. Okada Y, Klein NJ, van-Saene HK, Webb G, Holzel H, Pierro A: Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. *Ann Surg* 2000, 231:276-281.
  38. Okada Y, Papp E, Klein NJ, Pierro A: Total parenteral nutrition directly impairs cytokine production after bacterial challenge. *J Pediatr Surg* 1999, 34:277-280.
  39. Okada Y, Klein NJ, Pierro A: Neutrophil dysfunction: The cellular mechanism of impaired immunity during total parenteral nutrition in infancy. *J Pediatr Surg* 1999, 34:242-245.
  40. Chaet MS, Farrell MK, Ziegler MM, Warner BW: Intensive nutritional support and remedial surgical intervention for extreme short bowel syndrome. *J Pediatr Gastroenterol Nutr* 1994, 19:295-298.
  41. Bines J, Francis D, Hill D: Reducing parenteral requirement in children with short bowel syndrome: impact of an amino acid-based complete infant formula. *J Pediatr Gastroenterol Nutr* 1998, 26:123-128.
  42. Sondheimer JM, Cadnapaphornchai M, Sontag M, Zerbe GO: Predicting the duration of dependence on parenteral nutrition after neonatal intestinal resection. *J Pediatr* 1998, 132:80-84.
  43. Rossi TM, Lee PC, Young C, Tjota A: Small intestinal mucosa changes, including epithelial cell proliferative activity, of children receiving total parenteral nutrition (TPN). *Dig Dis Sci* 1993, 38:1608-1613
  44. Cooper HM: Synthesizing research : a guide for literature reviews. In *Applied social research methods series ; v 2* 3rd edition. Thousand Oaks, Calif., Sage Publications; 1998:xii, 201.
  45. Sakamoto K, Hirose H, Onizuka A, Hayashi M, Futamura N, Kawamura Y, Ezaki T: Quantitative study of changes in intestinal morphology and mucus gel on total parenteral nutrition in rats. *J Surg Res* 2000, 94:99-106.
  46. Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-Henken B: Effects of parenteral and enteral nutrition on gut-associated lymphoid tissue. *J Trauma* 1995, 39:44-51; discussion 51-2.
  47. Sedman PC, MacFie J, Palmer MD, Mitchell CJ, Sagar PM: Preoperative total parenteral nutrition is not associated with mucosal atrophy or bacterial translocation in humans. *Br J Surg* 1995, 82:1663-1667.
  48. Guedon C, Schmitz J, Lerebours E, Metayer J, Audran E, Hemet J, Colin R: Decreased brush border hydrolase activities without gross morphologic changes in human intestinal mucosa after prolonged total parenteral nutrition of adults. *Gastroenterology* 1986, 90:373-378.
  49. Buchman AL, Moukarzel AA, Bhuta S, Belle M, Ament ME, Eckhart CD, Hollander D, Gornbein J, Kopple JD, Vijayaraghavan SR: Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. *JPEN J Parenter Enteral Nutr* 1995, 19:453-460.
  50. Pironi L, Paganelli GM, Miglioli M, Biasco G, Santucci R, Ruggeri E, Di- Febo G, Barbara L: Morphologic and cytoproliferative patterns of duodenal mucosa in two patients after long-term total parenteral nutrition: changes with oral refeeding and relation to intestinal resection. *JPEN J Parenter Enteral Nutr* 1994, 18:351-354.
  51. Groos S, Hunefeld G, Luciano L: Parenteral versus enteral nutrition: morphological changes in human



- adult intestinal mucosa. *J Submicrosc Cytol Pathol* 1996, 28:61-74.
52. Moyer-Mileur L. Anthropometric and laboratory assessment of very low birth weight infants: the most helpful measurements and why. *Semin Perinatol.* 2007;31:96–103.
  53. Pagana KD, Pagana TJ, eds. *Mosby's Diagnostic and Laboratory Test Reference.* 8th ed. St Louis, MO: Mosby; 2007:755–756.
  54. Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. *J Am Diet Assoc.* 2004;104:1258–1264.
  55. Marshall WJ. Nutritional assessment: its role in the provision of nutrition support. *J Clin Pathol.* 2008;61:1083–1088.
  56. Johnson AM, Merlini G, Sheldon J, et al. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. *Clin Chem Lab Med.* 2007;45:419–426.
  57. Shulman RJ, Phillips S. Parenteral nutrition in infants and children. *J Pediatr Gastroenterol Nutr.* 2003;36(5):588–607.
  58. Kerner JA, Poole RL. The use of IV fats in neonates. *Nutr Clin Pract.* 2006;21:374–380.
  59. Siepler J. Principles and strategies for monitoring home parenteral nutrition. *Nutr Clin Pract.* 2007;22:340–350.
  60. Crook MA. Lipid clearance and total parenteral nutrition: the importance of monitoring plasma lipids. *Nutrition.* 2000;16:774–775.
  61. Crill CM, Helms RA. The use of carnitine in pediatric nutrition. *Nutr Clin Pract.* 2007;22:204–213.
  62. Borum PR. Carnitine in neonatal nutrition. *J Child Neurol.* 1995;10(suppl):2S25–2S31.
  63. Winter SC, Szabo-Aczel S, Curry CJ, et al. Plasma carnitine deficiency: clinical observations in 51 pediatric patients. *Am J Dis Child.* 1987;141:660–665.
  64. Tao RC, Yoshimura NN. Carnitine metabolism and its application in parenteral nutrition. *J Parenter Enteral Nutr.* 1980;4:469–486.
  65. Hamilton C, Austin T, Seidner DL. Essential fatty acid deficiency in human adults during parenteral nutrition. *Nutr Clin Pract.* 2006;21:387–394.
  66. Postuma R, Pease PW, Watts R, et al. Essential fatty acid deficiency in infants receiving parenteral nutrition. *J Pediatr Surg.* 1978;13:393–398.
  67. Panel on Macronutrients, Panel on the Definition of Dietary Fiber, Subcommittee on Upper Reference Levels of Nutrients, Subcommittee on Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. *Dietary Reference Intakes for Energy, Carbohydrate, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.* Washington DC: The National Academies Press; 2005:422–541.
  68. ([http://www.sickkids.ca/pdfs/Clinical-Dietitians/19499-Enteral\\_Parenteral\\_Nutrition.pdf](http://www.sickkids.ca/pdfs/Clinical-Dietitians/19499-Enteral_Parenteral_Nutrition.pdf), date of access: 05-02-2012.
- 